$PALI
PALISADE BIO, INC.

2019 Q1 Form 10-Q Financial Statement

#000117184319003354 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $2.500K $2.500K
YoY Change 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $940.0K $1.180M
YoY Change -20.34% -11.28%
% of Gross Profit
Research & Development $1.514M $1.169M
YoY Change 29.5% -59.7%
% of Gross Profit
Depreciation & Amortization $40.00K $70.00K
YoY Change -42.86% -36.36%
% of Gross Profit
Operating Expenses $2.459M $2.351M
YoY Change 4.57% -44.47%
Operating Profit -$2.457M -$2.349M
YoY Change 4.58% -44.49%
Interest Expense $2.017K $1.920K
YoY Change 5.05% -98.62%
% of Operating Profit
Other Income/Expense, Net -$657.4K $202.0K
YoY Change -425.42% -106.06%
Pretax Income -$3.110M -$2.150M
YoY Change 44.65% -71.6%
Income Tax
% Of Pretax Income
Net Earnings -$3.114M -$2.147M
YoY Change 45.04% -71.63%
Net Earnings / Revenue -124559.68% -85878.72%
Basic Earnings Per Share
Diluted Earnings Per Share -$20.73M -$16.54M
COMMON SHARES
Basic Shares Outstanding 18.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.010M $9.720M
YoY Change -58.74% -41.73%
Cash & Equivalents $4.005M $9.724M
Short-Term Investments $0.00
Other Short-Term Assets $300.0K $350.0K
YoY Change -14.29% -27.08%
Inventory
Prepaid Expenses $295.4K $347.0K
Receivables $237.8K $137.4K
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.538M $10.21M
YoY Change -55.54% -40.55%
LONG-TERM ASSETS
Property, Plant & Equipment $75.67K $149.7K
YoY Change -49.44% -38.36%
Goodwill
YoY Change
Intangibles $738.4K $839.3K
YoY Change -12.02% -7.23%
Long-Term Investments
YoY Change
Other Assets $53.35K $18.05K
YoY Change 195.62% 14.05%
Total Long-Term Assets $867.4K $1.341M
YoY Change -35.33% -13.81%
TOTAL ASSETS
Total Short-Term Assets $4.538M $10.21M
Total Long-Term Assets $867.4K $1.341M
Total Assets $5.406M $11.55M
YoY Change -53.2% -38.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.080M $1.170M
YoY Change -7.69% -46.08%
Accrued Expenses $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.210M $1.279M
YoY Change -5.39% -74.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $920.0K $3.660M
YoY Change -74.86% -6.15%
Total Long-Term Liabilities $920.0K $3.660M
YoY Change -74.86% -6.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.210M $1.279M
Total Long-Term Liabilities $920.0K $3.660M
Total Liabilities $2.134M $4.943M
YoY Change -56.83% -44.76%
SHAREHOLDERS EQUITY
Retained Earnings -$216.7M -$210.8M
YoY Change 2.79% 5.11%
Common Stock $182.1K $151.6K
YoY Change 20.09% 29.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.272M $6.607M
YoY Change
Total Liabilities & Shareholders Equity $5.406M $11.55M
YoY Change -53.2% -38.33%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$3.114M -$2.147M
YoY Change 45.04% -71.63%
Depreciation, Depletion And Amortization $40.00K $70.00K
YoY Change -42.86% -36.36%
Cash From Operating Activities -$1.666M -$1.847M
YoY Change -9.8% -58.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.000M
YoY Change -100.0%
Cash From Investing Activities $5.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -117.0K -104.2K
YoY Change 12.25% -111.31%
NET CHANGE
Cash From Operating Activities -1.666M -1.847M
Cash From Investing Activities 5.000M
Cash From Financing Activities -117.0K -104.2K
Net Change In Cash -1.783M 3.049M
YoY Change -158.48% -186.76%
FREE CASH FLOW
Cash From Operating Activities -$1.666M -$1.847M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
1083143
CY2018Q4 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
832564
CY2019Q1 cur Additional Research And Development Expense Due To Modifications
AdditionalResearchAndDevelopmentExpenseDueToModifications
102000
CY2019Q1 cur Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
95000
CY2018Q1 cur Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
84000
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
237782
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294057
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2156
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-413
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
219819771
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
219481805
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
238835
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
337966
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
337966
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238835
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13.5
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9.5
CY2019Q1 us-gaap Assets
Assets
5405703
CY2018Q4 us-gaap Assets
Assets
7684450
CY2019Q1 us-gaap Assets Current
AssetsCurrent
4538277
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6508393
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4005089
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5787110
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6674940
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9724248
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1782021
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3049308
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18205060
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18205060
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18205060
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18205060
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
182051
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
182051
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3115735
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2146853
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
39821
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
67374
CY2019Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-340115
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
190219
CY2019Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
923849
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
583734
CY2019Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
63938
CY2019Q1 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
CY2018Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
298238
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-56275
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-175430
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-418625
CY2019Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-362176
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
903
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
501
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P292D
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
250000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
944602
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1182054
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
244319
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
293119
CY2018Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-89937
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-27648
CY2018Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-7369
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-19125
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-704
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-75938
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-56241
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
738404
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
763543
CY2019Q1 us-gaap Interest Expense
InterestExpense
2017
CY2018Q1 us-gaap Interest Expense
InterestExpense
1920
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
2017
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
1920
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
17749
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1275
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
49600
CY2019Q1 us-gaap Liabilities
Liabilities
2133922
CY2018Q4 us-gaap Liabilities
Liabilities
1634900
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5405703
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7684450
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1210073
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1051166
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-117019
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-104244
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1665905
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1846949
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2146968
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3113992
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-657427
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
202027
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2459065
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2351495
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2456565
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2348995
CY2018Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
29800
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
47300
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1795786
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
238835
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10900000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
47100
CY2019Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
62200
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53354
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23965
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
115
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1743
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1743
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
115
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
126930
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
218602
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-344295
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4021
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295406
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
363288
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2018Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
5000000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75668
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90311
CY2019Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
117019
CY2018Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
104244
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1514463
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1169441
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.78
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
800000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.34
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19040
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1632662
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2432662
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.78
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216737885
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213623893
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2500
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2500
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
337966
CY2019Q1 us-gaap Sublease Income
SubleaseIncome
24200
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.37
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.43
CY2019Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2432662
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5712
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y109D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y146D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y36D
CY2019Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.37
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
8515129
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
6607111
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6049550
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3271781
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div></div></div></div></div></div></div></div></div></div>
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18216421
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15116937

Files In Submission

Name View Source Status
0001171843-19-003354-index-headers.html Edgar Link pending
0001171843-19-003354-index.html Edgar Link pending
0001171843-19-003354.txt Edgar Link pending
0001171843-19-003354-xbrl.zip Edgar Link pending
cur-20190331.xml Edgar Link completed
cur-20190331.xsd Edgar Link pending
cur-20190331_cal.xml Edgar Link unprocessable
cur-20190331_def.xml Edgar Link unprocessable
cur-20190331_lab.xml Edgar Link unprocessable
cur-20190331_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_440.htm Edgar Link pending
f10q_051419p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending